NCT04706923 - A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Adenovirus InfectionsCytomegalovirus Infection

Interventions

DRUG

BCV

Brincidofovir (BCV) is a lipid conjugate of the antiviral cidofovir that enables optimal intracellular levels of the active drug.

Trial Locations (11)

19104

RECRUITING

Research Site, Philadelphia

27710

RECRUITING

Research Site, Durham

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

60637

RECRUITING

Research Site, Chicago

68198

RECRUITING

University of Nebraska Medical Center, Omaha

77030

RECRUITING

MD Anderson Cancer Center, Houston

90027

RECRUITING

Research Site, Los Angeles

90095

COMPLETED

Research Site, Los Angeles

94158

COMPLETED

Research Site, San Francisco

98109

RECRUITING

Research Site, Seattle